UNSPSC 51202411: Natalizumab

This classification denotes an immunosuppressant and antineoplastic monoclonal antibody and multiple sclerosis treatment, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 3JB47N2Q2P. The term NATALIZUMAB is an International Non-Proprietary Name or INN. European Medicines Agency schedules natalizumab in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB22282. Most nations, for tariff and trade purposes, schedule natalizumab under HS 30021091 and SITC 54163.

As of Q4 2014, NATALIZUMAB remains US FDA's Preferred Term for this commodity. Natalizumab bears US NLM identifiers UMLS ID C0665297 and NCI Concept Code C77862. SMILES: none.

UNSPSC 51202411 Natalizumab, a Commodity code, does not align with the recent state and local contract opportunities posted under this classification. The code nominally denotes a specific monoclonal antibody pharmaceutical used to treat multiple sclerosis and Crohn's disease; however, the recent solicitations show little activity targeting natalizumab procurement itself. Instead, the opportunities tagged to this code reflect a broader mix of pharmaceutical and medical supply categories — naloxone distribution systems, generic multi-source pharmaceuticals through cooperative purchasing, direct-to-manufacturer prescription programs, and emergency medical supplies for fire departments — that diverge significantly from the code's specific therapeutic scope.

The issuing bodies pursuing pharmaceutical and medical supply procurement include state health and human services agencies (Texas HHS Commission), state-administered cooperative purchasing organizations (Minnesota Multistate Cooperative Purchasing Alliance, serving Minnesota, Oregon, and member jurisdictions), county health departments (Seminole County, Florida), and municipal fire and emergency services (City of Tampa). Recent representative opportunities include the Minnesota Multistate Cooperative Purchasing Alliance issuing an RFP for generic multi-source pharmaceuticals and OTC products with a response deadline of March 26, 2026; the Texas Health and Human Services Commission issuing an RFI on Therapeutic Pharmacy Initiative direct-to-manufacturer prescriptions posted April 3, 2026; Seminole County, Florida soliciting naloxone and drug deactivation systems through an IFB with a July 26, 2026 response deadline; and the City of Tampa issuing a sheltered-market IFB for medical and first aid supplies designated for the Tampa Fire Department Rescue Division, due March 13, 2026, with an estimated contract value of $700,000. The code shows recent activity concentrated in Florida and across the upper Midwest and Southwest, but the mismatch between the natalizumab classification and the pharmaceutical categories actually being solicited suggests this code is not the primary vehicle for natalizumab procurement at the state and local level.